Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR-T for MRD-Positive B-Cell ALL
NCT03919526Phase 1Completed
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2019
- Primary completion
- Nov 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/CD22 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai General Hospital. Primary endpoint: Occurrence of study related adverse effects defined by NCI CTCAE 5.0. Started Aug 2019; status: completed.
02
Drugs
anti-CD19/CD22 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03919526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919526.